Stock market today: Stocks fall as investors rotate out of tech into Jackson Hole
SALT LAKE CITY - Sera Prognostics Inc. (NASDAQ:SERA), a company focused on improving maternal and neonatal health, reported fourth quarter 2024 financial results that exceeded analyst expectations for revenue, sending shares up 3.6% in after-hours trading.
The pregnancy biomarker company posted revenue of $24,000 for the quarter, surpassing the consensus estimate of $16,750. However, this represents a 41.5% decline from $41,000 in the same quarter last year. Adjusted earnings per share came in at -$0.25, slightly below analyst projections of -$0.24.
For the full year 2024, Sera Prognostics reported total revenue of $77,000, down 74.8% YoY from $306,000 in 2023. The company’s net loss narrowed to $32.9 million in 2024 from $36.2 million the previous year.
"We are pleased with our progress during the year and, more recently, with the results of our full PRIME study," said Zhenya Lindgardt, President and CEO of Sera Prognostics.
The company highlighted recent developments, including positive results from its PRIME study showing reductions in neonatal morbidity and mortality. Sera Prognostics also raised $57.5 million through a public offering in February 2025, extending its cash runway through 2028.
Total (EPA:TTEF) operating expenses for Q4 2024 increased 6% YoY to $9.4 million. Research and development expenses decreased 19% to $3.1 million, while selling, general and administrative expenses rose to $6.3 million from $5.0 million in Q4 2023.
As of December 31, 2024, Sera Prognostics had cash, cash equivalents, and available-for-sale securities of approximately $68.2 million. The company plans to use its recent fundraising proceeds to expand commercial efforts in the United States and accelerate preparations for expansion in the European Union.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.